Latest Breaking News On - Head of oncology development - Page 1 : comparemela.com

Astellas' XTANDItm (Enzalutamide) Granted European Commission Approval for Use in Additional Recurrent Early Prostate Cancer Treatment Setting

Astellas' XTANDItm (Enzalutamide) Granted European Commission Approval for Use in Additional Recurrent Early Prostate Cancer Treatment Setting
lelezard.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from lelezard.com Daily Mail and Mail on Sunday newspapers.

Japan
Barcelona
Comunidad-autonoma-de-cataluna
Spain
Canada
Tokyo
United-states
American
America
Ahsan-arozullah
Antonio-alcaraz
American-society-of-clinical-oncology

Astellas' XTANDI™ (Enzalutamide) Granted European Commission Approval for Use in Additional Recurrent Early Prostate Cancer Treatment Setting

Astellas' XTANDI™ (Enzalutamide) Granted European Commission Approval for Use in Additional Recurrent Early Prostate Cancer Treatment Setting
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

Japan
Barcelona
Comunidad-autonoma-de-cataluna
Spain
Canada
Tokyo
United-states
America
Antonio-alcaraz
Ahsan-arozullah
Drug-administration
University-hospital-clinic-of-barcelona

Pfizer (PFE) Announces EMA Validates Type II Variation Application for PADCEV with KEYTRUDA for First-Line Treatment of Advanced Bladder Cancer

Pfizer (PFE) Announces EMA Validates Type II Variation Application for PADCEV with KEYTRUDA for First-Line Treatment of Advanced Bladder Cancer
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

Ahsan-arozullah
Naoki-okamura
Roger-dansey
Astellas-pharma-inc
European-society-for-medical-oncology
Committee-for-medicinal-products-human-use
Head-of-oncology-development
Pfizer-inc
European-medicines-agency
Drug-administration
European-commission

European Medicines Agency Validates Type II Variation Application for PADCEV® (enfortumab vedotin) with KEYTRUDA® (pembrolizumab) for First-Line Treatment of Advanced Bladder Cancer

European Medicines Agency Validates Type II Variation Application for PADCEV® (enfortumab vedotin) with KEYTRUDA® (pembrolizumab) for First-Line Treatment of Advanced Bladder Cancer
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

Tokyo
Japan
United-states
Canada
American
Naoki-okamura
Ahsan-arozullah
Roger-dansey
Drug-administration
European-society-for-medical-oncology
International-agency-for-research-on-cancer
Merck-sharp-dohme-corp